tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Precancerous Conditions D011230 48 associated lipids
Psoriasis D011565 47 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Leukemia P388 D007941 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Arthritis D001168 41 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nervous System Diseases D009422 37 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Glomerulonephritis D005921 35 associated lipids
Acne Vulgaris D000152 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Fever D005334 35 associated lipids
Burns D002056 34 associated lipids
Cataract D002386 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Diarrhea D003967 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Stroke D020521 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Liver Diseases D008107 31 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Kidney Diseases D007674 29 associated lipids
Obesity D009765 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Cholestasis D002779 23 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Fibrosis D005355 23 associated lipids
Cystitis D003556 23 associated lipids
Hypersensitivity D006967 22 associated lipids
Erythema D004890 22 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ishida A et al. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysis. 1998 Transfusion pmid:9738624
Allen C et al. Polycaprolactone-b-poly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. 1998 Sep-Oct Bioconjug. Chem. pmid:9736490
Hodak SP et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. 1998 Transplantation pmid:9734501
Wiesner RH A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. 1998 Transplantation pmid:9734494
Sussman MA et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. 1998 Science pmid:9733519
Cogill JL et al. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. 1998 Clin. Chem. pmid:9732981
Kawahara K et al. Tracheal transplantation for carinal reconstruction in dogs. 1998 J. Thorac. Cardiovasc. Surg. pmid:9731780
Meiser BM et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. 1998 J. Heart Lung Transplant. pmid:9730427
Reichart B et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. 1998 J. Heart Lung Transplant. pmid:9730426
Horning NR et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. 1998 J. Heart Lung Transplant. pmid:9730424
Winter C et al. MAP kinase phosphatase 1 is expressed and enhanced by FK506 in surviving mamillary, but not degenerating nigral neurons following axotomy. 1998 Brain Res. pmid:9729383
Gammie JS et al. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment. 1998 Exp. Hematol. pmid:9728927
Snyder SH et al. Immunophilins in the nervous system. 1998 Neuron pmid:9728910
Garcia-Cozar FJ et al. Two-site interaction of nuclear factor of activated T cells with activated calcineurin. 1998 J. Biol. Chem. pmid:9727000
Reddy SS and Holley JL Nocardiosis in a recently transplanted renal patient. 1998 Clin. Nephrol. pmid:9725785
Thielke J et al. Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome. 1998 Liver Transpl Surg pmid:9724482
Herzberg GZ et al. Usefulness of tacrolimus versus cyclosporine after pediatric heart transplantation. 1998 Am. J. Cardiol. pmid:9723652
Miyata Y et al. Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation. 1998 Transplant. Proc. pmid:9723548
Hanack U et al. Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation? 1998 Transplant. Proc. pmid:9723477
Fritsche L et al. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. 1998 Transplant. Proc. pmid:9723451
Pirsch JD Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic. 1998 Transplant. Proc. pmid:9723448
Xu M et al. FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. 1998 Transplant. Proc. pmid:9723447
Yonan NA et al. Tracheal allograft transplantation in rats: the role of immunosuppressive agents in development of obliterative airway disease. 1998 Transplant. Proc. pmid:9723443
Perego C et al. Study of the immunosuppressive effect of SMS 201-995 and its synergic action with FK 506. 1998 Transplant. Proc. pmid:9723434
Jonas S et al. Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation. 1998 Transplant. Proc. pmid:9723433
Busuttil RW and Holt CD Tacrolimus is superior to cyclosporine in liver transplantation. 1998 Transplant. Proc. pmid:9723432
Vanrenterghem Y Tacrolimus (FK 506) in kidney transplantation. 1998 Transplant. Proc. pmid:9723431
Halloran PF et al. Calcineurin and the biological effect of cyclosporine and tacrolimus. 1998 Transplant. Proc. pmid:9723430
Otto C et al. Selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats. 1998 Transplant. Proc. pmid:9723426
Kohnle M et al. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. 1998 Transplant. Proc. pmid:9723413
Atillasoy E et al. Cholesterol levels long-term after liver transplant. 1998 Transplant. Proc. pmid:9723387
Varghese Z et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. 1998 Transplant. Proc. pmid:9723384
Donadio C et al. Tubular damage and impairment of renal function in transplanted kidneys. 1998 Transplant. Proc. pmid:9723381
Burrows L et al. Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients. 1998 Transplant. Proc. pmid:9723378
Yoshimura R et al. Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. 1998 Transplant. Proc. pmid:9723373
Curtis JJ Posttransplant hypertension. 1998 Transplant. Proc. pmid:9723370
Falkenstein K and Dunn S Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient. 1998 Transplant. Proc. pmid:9723354
Ettenger RB New immunosuppressive agents in pediatric renal transplantation. 1998 Transplant. Proc. pmid:9723350
Berweck S et al. Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9723345
Behr TM et al. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A. 1998 Transplant. Proc. pmid:9723333
Lang M et al. Combined liver-kidney transplantation: long-term follow-up in 18 patients. 1998 Transplant. Proc. pmid:9723313
Lagget M et al. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. 1998 Transplant. Proc. pmid:9723312
Gridelli B et al. Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723311
Alberti D et al. Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation. 1998 Transplant. Proc. pmid:9723310
Reggiani P et al. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression. 1998 Transplant. Proc. pmid:9723308
Rayes N et al. Distribution of lymphocyte subtypes in liver transplant recipients with viral reinfection or de novo malignancy. 1998 Transplant. Proc. pmid:9723303
Peeters P et al. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group. 1998 Transplant. Proc. pmid:9723301
Van Buren D et al. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. 1998 Transplant. Proc. pmid:9723299
McMaster P et al. Liver transplantation: changing goals in immunosuppression. 1998 Transplant. Proc. pmid:9723295
Levy GA Neoral is superior to FK 506 in liver transplantation. 1998 Transplant. Proc. pmid:9723293